NatiVita has registered drugs in Moldova

NatiVita has registered the first medicinal products in the Republic of Moldova. In the near future, two drugs will immediately receive registration certificates: T-Mab (Trastuzumab) and B-Mab (Bevacizumab). T-Mab and B-Mab are the first drugs registered by NatiVita outside Belarus.

Reference
T-Mab (Trastuzumab) — monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat HER2 positive (HER2+) certain breast and stomach cancers. Trastusumab increases the overall survival of patients with breast and stomach cancer, prolongs disease-free survival and improves the quality of life. Local production of Trastusumab` biosimilar will increase the availability of personalized therapy and will allow to save patients’ lives.

B-Mab (Bevacizumab) — drug that slows the growth of new blood vessels. Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Bevacizumab is approved to treat metastatic colorectal cancer, metastatic HER2-negative breast cancer, certain lung cancer, metastatic kidney cancer, ovarian and cervical cancers. Bevacisumab` inclusion into chemotherapy regimens significantly improves the effectiveness of treatment